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Abstract
Background and purposes: Anticoagulant therapy is recommended for the secondary prevention of stroke in patients with atrial fibrillation (AF). The identification of patients at high risk for early recurrence, which are potential candidates to prompt anticoagulation, is crucial to justify the risk of bleeding associated with early anticoagulant treatment. The aim of this study was to evaluate in patients with acute ischemic stroke and AF the association between findings at trans-thoracic echocardiography (TTE) and 90 day recurrence.
Methods:
In consecutive patients with acute ischemic stroke and AF, TTE was performed within 7 days from hospital admission. Study outcomes were recurrent ischemic cerebrovascular events (stroke or TIA) and systemic embolism.
Results: 854 patients (mean age 76.3±9.5 years) underwent a TTE evaluation; 63 patients (7.4%) had at least a study outcome event. Left atrial thrombosis was present in 11 patients (1.3%) among whom 1 had recurrent ischemic event. Left atrial enlargement was present in 548 patients (64.2%) among whom 51 (9.3%) had recurrent ischemic events. The recurrence rate in the 197 patients with severe left atrial enlargement was 11.7%. On multivariate analysis, the presence of atrial enlargement (OR=2.13; 95% CI 1.06-4.29, p=0.033) and CHA2DS2-VASc score (OR 1.22; 95% CI 1.04-1.45, p=0.018, for each point increase) were correlated with ischemic recurrences.
Conclusion:
In patients with AF-associated acute stroke, left atrial enlargement is an independent marker of recurrent stroke and systemic embolism. The risk of recurrence is accounted for by severe atrial enlargement. TTE-detected left atrial thrombosis is relatively uncommon.
Background
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an elevated risk of ischemic stroke and systemic thromboembolism. After an acute stroke, patients with AF have a high risk of early recurrence that is about 8% within 90 days from the acute event (1).
Anticoagulant therapy is effective for the secondary prevention of stroke in patients with AF. The balance between the risk of recurrence and bleeding associated to anticoagulant therapy for any given patient remains unclear. The identification of patients at high risk for early recurrence, which are potential candidates to prompt anticoagulation, is crucial to justify the risk of bleeding associated with early anticoagulant treatment.
Echocardiography, transthoracic (TTE) or less commonly transesophageal (TEE), is included in the work-up of patients with AF and stroke. In these patients, echocardiography detected left atrial thrombosis supports early anticoagulation (2).
Likewise, in patients with acute stroke, left atrial enlargement, has been associated with the risk of stroke recurrence (3).
The aim of this study was to evaluate the potential association between TTE findings in the early stage of cerebral ischemia (within 7 days from hospital admission) and the risk of 90-day thromboembolic recurrence in patients with acute ischemic stroke and AF.
Methods

Patients
Data for this analysis were extracted from the database of a prospective multicentre study which enrolled consecutive patients with acute stroke and AF (the RAF study) (1).
This study, carried out between January 2012 and March 2014, enrolled 1,029 consecutive patients in 29 Stroke Units from Europe and Asia.
On admission, the severity of acute stroke was assessed using the National Institutes of Health Stroke Scale (NIHSS); all investigators were certified about the use of this scale.
AF was classified as paroxysmal (episodes terminating spontaneously within 7 days), persistent (episodes lasting more than 7 days requiring pharmacologic and/or electrical stimulation), or permanent (persisting for more than 1 year, either because cardioversion failed or was not attempted).
Risk factors
Data on known stroke risk factors were collected as reported in the main paper (1). 
Echocardiogram evaluation
TTE was performed within 7 days form stroke onset by a local cardiologist using a standardized protocol. Patients were imaged in the left lateral decubitus. Images were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal (standard long-and short-axis images) and apical views (standard long-axis, 2-and 4-chamber images). Standard 2-dimensional and color Doppler data, triggered to the QRS complex, were saved in cine loop format. Pulsed and continuous wave Doppler data were also stored digitally.
TTE analysis included the presence of: 1) intra-cardiac thrombus; 2) left atrial enlargement; 3) mitral valve stenosis or regurgitation; 4) aortic valve stenosis or regurgitation; 5) tricuspidal valve stenosis or regurgitation; 6) dilated cardiomyopathy with left ventricular ejection ≤40%. Presence of pacemaker, biological or mechanical valve (mitral or aortic) was also assessed.
The presence of an intra-cardiac thrombus was diagnosed by the presence of an echodense mass distinct from the endocardium in any cardiac cavity (7).
Left atrial enlargement was defined following the American Society of Echocardiography guidelines measuring the left atrial diameter or volume taking into account the difference between sexes (8). The severity of atrial enlargement was defined according the definitions described in table 1.
Mitral, aortic and tricuspid stenoses or regurgitations were dichotomized as absent or present (mild/moderate/severe) following the definitions of published guidelines (9,10).
Evaluation of outcome
Patients were followed-up prospectively by office or telephone interviews. Study outcome was the composite of recurrent ischemic cerebrovascular events (stroke or TIA) and symptomatic systemic embolisms. Recurrent ischemic stroke was defined as the sudden onset of a new focal neurological deficit of vascular origin in a site consistent with the territory of a major cerebral artery and after exclusion of cerebral hemorrhage at neuroimaging. TIA was defined as a transient episode of neurological dysfunction caused by focal brain ischemia without acute infarction. Systemic embolism was defined as an acute vascular occlusion of an extremity or organ confirmed by imaging, surgery, or autopsy. The diagnosis of systemic embolism was independently adjudicated by vascular surgeons.
Statistical analysis
Differences in the characteristics of patients with or without outcome events were tested using χ-square test. Correlations between TTE characteristics and risk of recurrent ischemic events were sought by multiple logistic regression analysis. The variables included in the model other than the TTE characteristics were the type of AF, CHA2DS2-VASc score, cardiovascular risk factors, reperfusion therapy, the severity of stroke on admission according to NIHSS score, the presence of pacemaker, biological or mechanical valve, anti-thrombotic treatment and size of the lesion.
The relationship between the recurrent ischemic events and the TTE characteristics, correlated to outcome on multivariate analysis, were also explored with Cox proportional hazard models. The Cox model provides an estimate of the effect of TTE characteristics on recurrent ischemic events after adjusting for: lesion sizes, age, sex, type of AF, NIHSS on admission, anticoagulant treatment, the presence of pacemaker and the histories of hypertension, diabetes, previous stroke/TIA and congestive heart failure.
Results
Overall, 1,037 consecutive patients were included in the study. Of these, 8 patients were excluded for incomplete data while 1,029 patients were included in the analysis; of these, 2.05; 95% CI 1.08-2.87, p=0.027). All the remaining TTE characteristics were not correlated with outcome event. Figure 2 shows the adjusted analysis using the Cox regression model that evidences the different risk for an ischemic outcome event according to the severity of atrial enlargement within 90 days. This analysis, was adjusted for age, sex, CHA2DS2-VASc score, lesion size, anticoagulant therapy and NIHSS score on admission.
Discussion
In this prospective study in patients with acute stroke and AF, TTE showed a left atrial thrombus in about 1% and an atrial enlargement in 65% of the patients. The presence of atrial enlargement was associated with a higher risk of an ischemic recurrence within 90 days. This association was accounted for by severe atrial enlargement.
In clinical practice, for the fear of an early recurrence, TTE is usually performed in acute phase of stroke to detect a thrombus and to start anticoagulant therapy earlier. This study showed the futility of acute TTE for detection of intra-cardiac thrombosis. About 17% of the patients did not undergo TTE in the acute phase of stroke and these patients were older and with more severe neurological deficit. Therefore, it is possible that in these patients, the rate of intra-cardiac thrombus was higher. However, these are not the typical patients in whom anticoagulation would be started promptly.
Several studies demonstrated that TEE is superior to TTE for identification of a cardiac embolic source in patients with TIA or stroke (11, 12) . De Brujn et al. (11) , in patients with acute stroke, found a thrombus in 17% of the patients using TEE compared to 2% using TTE. Thus, in patients with acute stroke and AF, TEE is probably more useful to detect intra-cardiac thrombosis. However, this examination in patients with acute stroke is not easy.
Our study showed that atrial enlargement, especially severe, was independently associated with early stroke recurrence. Several studies found that moderate to severe left atrial enlargement is an independent marker of recurrent stroke of embolic subtypes in patients with ischemic stroke even in patients without evidence of AF (3, 13) .
Furthermore, atrial dilatation is correlated with more severe stroke (14) .
An association between ischemic recurrent events and the presence of a valve prosthesis, biological or mechanical, was not found but the number of patients with valve prosthesis was low (17 patients with biological prosthesis and 40 with mechanical prosthesis).
This study has several limitations and strengths. The evaluation of TTE and the adjudication of the outcome events were not centralized. Not all the patients had TTE examination and this might have introduced some selection bias.
Strengths of our study include the prospective and multicentre design with an adequate sample size of consecutive patients, making the results robust and generalizable.
Furthermore, we collected data on a wide range of potentially confounding risk factors, allowing us to estimate the independent effects of TTE characteristics evaluated.
In summary, in patients with AF-associated acute stroke, atrial enlargement is an independent marker of recurrent stroke and systemic embolism. Left atrial thrombosis is relatively uncommon. Future studies are needed to evaluate whether left atrial enlargement could be used to drive prompt anticoagulant therapy in patients with acute stroke and AF to reduce the risk of recurrence. 
